New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For IPSEY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
05:15 EDTIPSEYActive Biotech AB, Ipsen discontinue development of tasquinimod
Active Biotech (ACTI) and Ipsen (IPSEY) announced top line results of the 10TASQ10 study. While the study showed that tasquinimod reduced the risk of radiographic cancer progression or death compared to placebo in patients with metastatic castration resistant prostate cancer, or mCRPC, who have not received chemotherapy, tasquinimod did not extend overall survival. Efficacy results together with preliminary safety data do not support positive benefit risk balance in this population. Therefore the companies have decided to discontinue all studies in prostate cancer. Full results will be presented at an upcoming scientific conference.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use